Traditionally, biologists have been constrained by analytical techniques that sacrifice spatial information, reducing tissues to a mixture of cells where location is lost. This limitation has hindered our comprehension of how cellular neighborhoods influence physiological and pathological states. The emergence of spatial transcriptomics and proteomics now permits high-resolution mapping of RNA and protein molecules inside intact tissues, lending an unprecedented spatial dimension to molecular profiling. Spatial transcriptomics reveals the location-specific gene expression patterns, whereas spatial proteomics identifies the distribution and interplay of functional proteins, thereby elucidating the molecular choreography underlying cellular behavior.

IRB Barcelona’s new platform uniquely integrates multiple core technologies encompassing spatial genomics, proteomics, histopathology, advanced microscopy, and bioinformatics into a seamless workflow designed to generate comprehensive spatially resolved molecular maps. This integrated approach not only enables rigorous sample processing and data acquisition but also incorporates sophisticated computational tools to interpret multilayered datasets. By combining these modalities, researchers can create detailed molecular atlases that reveal how distinct cell types and molecular states coalesce to maintain tissue homeostasis or drive disease progression.

The launch of this platform reflects IRB Barcelona’s longstanding commitment to pioneering technologies that push the boundaries of molecular biology. Over the last two decades, the institute has been a trailblazer in genomic microarrays and single-cell gene expression profiling from minimal samples, establishing itself as a reference center of excellence. Their prior innovations in proteomics, including advanced top-down analysis techniques, and the adoption of light-sheet microscopy for three-dimensional tissue imaging, have laid the foundation for this next leap forward into spatial biology.

This powerful platform facilitates detailed investigation of a wide array of diseases characterized by complex tissue architecture, including cancer, neurodegenerative disorders, cardiovascular ailments, and immune dysfunction. For instance, in oncology, spatial omics can elucidate the cellular heterogeneity within tumors, map the spatial distribution of resistant cell subpopulations, and unravel cellular interactions that influence tumor microenvironment and therapy response. Such spatially-informed molecular data are critical for understanding why certain therapies fail and for identifying novel, spatially targeted therapeutic interventions.

The uniqueness of IRB Barcelona’s initiative lies not only in its technological sophistication but also in its multidisciplinary and collaborative framework. By coordinating expertise from multiple core facilities, the platform delivers an end-to-end pipeline that spans from sample preparation to deep computational analysis. This holistic integration ensures scientific robustness, reproducibility, and the generation of high-resolution spatial datasets that can be cross-compared across studies and over time, accelerating discovery and translational applications.

Moreover, this platform serves as a national hub and a collaborative nexus, opening its infrastructure to the wider scientific community, including academic institutions, hospitals, and industry collaborators. Such open access fosters synergy, drives innovation, and broadens the impact of spatial omics technologies across Spain and internationally. It is envisaged that this initiative will significantly propel precision medicine, enabling patient-specific molecular diagnostics and the development of personalized therapeutic strategies grounded in spatial cellular biology.

A critical aspect of this platform is its integration of advanced computational methods. Spatial omics generates complex, multilayered data that requires novel bioinformatics algorithms to align and co-analyze transcriptomic, proteomic, and phenotypic information within spatial coordinates. IRB Barcelona’s bioinformatics teams are developing and implementing these sophisticated pipelines to construct multidimensional molecular landscapes of tissues. Such atlases not only enhance our understanding of tissue organization and function but also provide invaluable resources for hypothesis generation and mechanistic studies.

The platform is also a testament to successful collaborative funding efforts, having been supported by Spanish and Catalan governmental bodies, Next Generation funds, and prominent foundations such as the Spanish Association Against Cancer, La Caixa Foundation, and the BBVA Foundation. This financial backing underscores the importance and potential impact of spatial omics on public health and biomedical research.

Looking ahead, the integration of spatial omics with other emerging technologies such as single-cell multi-omics and advanced imaging modalities promises to unlock even deeper insights into cellular ecosystems. The ability to spatially resolve multiple biomolecular layers simultaneously will provide a holistic view of biological systems, bridging the gap between molecular detail and tissue physiology. This comprehensive understanding is essential to confront the complexities of human diseases and to develop innovative treatment paradigms.

By enabling researchers to ‘see biology in place’, IRB Barcelona’s Spatial Omics Platform is not merely an incremental technological upgrade but represents a paradigm shift in life sciences. It turns the metaphor of the body as a city into a tangible reality, where cells, genes, and proteins are mapped with neighborhood precision. This spatial perspective is critical for decoding cellular behavior within the rich tapestry of tissue architecture and microenvironmental influences, ultimately advancing both basic biology and precision medicine.

In sum, this pioneering facility positions IRB Barcelona at the forefront of spatial biology, empowering scientists to unlock the spatial dimension of molecular biology that has remained elusive until now. The resulting knowledge is expected to transform our approach to diagnosing, treating, and preventing diseases with unprecedented accuracy and specificity, heralding a new era in biomedical research.

Subject of Research: Spatial Omics, Spatial Transcriptomics, Spatial Proteomics, Integrated Molecular Profiling

Article Title: IRB Barcelona Launches Spain’s First Integrated Spatial Omics Platform Revolutionizing Molecular Mapping in Tissues

News Publication Date: 9 February 2026

Image Credits: IRB Barcelona

Keywords: Genomics, Proteomics, Microscopy, Cancer, Bioinformatics, Health and Medicine

At the heart of this pioneering study lies the utilization of single-cell transcriptomics, a powerful tool that allows researchers to dissect the gene expression profiles of individual cells within the ovarian endometriomas. By isolating and analyzing thousands of cells at unprecedented resolution, the investigators were able to characterize the cellular heterogeneity within these lesions, identifying distinct cellular subpopulations contributing to disease pathology. This granular perspective provides critical insights into how specific cell types interact within the complex microenvironment of the ovary, enabling a refined understanding of disease mechanisms that had previously remained obscured.

Complementing the transcriptional data, the team integrated spatially resolved omics techniques to map the distribution of metabolic activities directly within the tissue architecture of ovarian endometriomas. This spatial dimension is a major leap forward, as it contextualizes molecular information within the physical landscape of the lesion, revealing how metabolic rewiring accompanies and possibly fuels disease progression. Importantly, these spatial maps highlighted distinct metabolic niches, underlining the metabolic heterogeneity that correlates with various cellular states and local microenvironmental cues.

One of the most compelling revelations from this study is the identification of unique transcriptional signatures that define the abnormal cellular phenotypes characteristic of ovarian endometriomas. These signatures include the upregulation of genes involved in inflammation, extracellular matrix remodeling, and angiogenesis, which collectively orchestrate the aggressive behavior of the lesions. Such a molecular blueprint underscores the dynamic interplay between immune responses and stromal compartment remodeling, painting a detailed portrait of the pathological landscape that sustains and exacerbates the disease.

Moreover, the metabolomic component of the investigation uncovered profound alterations in energy metabolism pathways within the affected ovarian tissue. The lesions exhibited a pronounced shift toward glycolytic metabolism, reminiscent of the Warburg effect observed in malignant tumors, despite ovarian endometriomas being benign. This metabolic reprogramming may serve as both a driver and consequence of the chronic inflammatory milieu, fostering an environment conducive to lesion persistence and resistance to conventional therapies.

The integration of single-cell and spatial omics data not only illuminates the molecular underpinnings of ovarian endometriomas but also opens avenues for the identification of potential biomarkers for diagnosis and therapeutic targets. By spotlighting specific metabolic enzymes and regulatory molecules dysregulated within discrete cellular subsets, the study lays the groundwork for precision medicine approaches tailored to the unique molecular fingerprints of individual lesions.

Importantly, this research addresses a critical gap in the study of endometriosis, a condition affecting millions worldwide yet marked by diagnostic challenges and limited treatment options. The complexity and variability of ovarian endometriomas have historically hindered effective clinical management. This comprehensive molecular atlas may thus catalyze a paradigm shift, enabling earlier detection, stratification of patients based on molecular features, and the development of targeted interventions that disrupt key pathological pathways.

Beyond the direct clinical implications, the methodology exemplified here represents a versatile blueprint applicable to a wide range of diseases characterized by tissue heterogeneity and metabolic dysregulation. The combination of single-cell transcriptomics with spatial metabolic profiling establishes a robust platform for unraveling the cellular composition and functional states within complex tissue environments, offering unprecedented resolution and contextual insight.

From a technical standpoint, the team harnessed advanced bioinformatics pipelines to integrate multi-omics datasets, tackling challenges associated with data dimensionality, batch effects, and spatial registration. Sophisticated clustering algorithms and network analysis tools facilitated the extraction of biologically meaningful patterns, while spatial mapping was enabled through innovative imaging mass spectrometry techniques that quantified metabolites with high spatial fidelity.

The implications of this work extend to the broader field of gynecologic pathology, where similar spatial and transcriptional complexities govern disease behavior. By delineating the cellular and metabolic topography of ovarian endometriomas, the study contributes to a deeper understanding of the interplay between cellular identity, metabolic state, and tissue architecture—a nexus fundamental to disease phenotypes.

Furthermore, the findings spotlight the role of microenvironmental factors in shaping metabolic adaptations. Hypoxia, immune cell infiltration, and stromal interactions likely converge to drive the observed metabolic rewiring and transcriptional shifts, suggesting that therapeutic strategies should consider not only the aberrant cells but also their surrounding niche.

The rich dataset generated also provides a valuable resource for the research community, enabling hypothesis generation and validation in other contexts of ovarian pathology. Future studies will undoubtedly build upon this foundation, exploring longitudinal changes, treatment responses, and the link between molecular signatures and clinical outcomes.

In summary, this seminal study harnesses the synergy of single-cell and spatial omics to deliver unprecedented insights into the molecular and metabolic intricacies of ovarian endometriomas. It paves the way for innovative diagnostic and therapeutic strategies that promise to improve the lives of countless women afflicted by this challenging condition. As omics technologies continue to mature, their integration will be critical in dissecting the cellular ecosystems underpinning complex diseases and translating fundamental discoveries into clinical breakthroughs.

Subject of Research:
Single-cell and spatially resolved omics analysis of ovarian endometriomas revealing underlying transcriptional and metabolic alterations.

Article Title:
Single-cell and spatially resolved omics reveal transcriptional and metabolic signatures of ovarian endometriomas.

Article References:
Qi, Y., Chen, X., Zheng, S. et al. Single-cell and spatially resolved omics reveal transcriptional and metabolic signatures of ovarian endometriomas. Nat Commun (2025). https://doi.org/10.1038/s41467-025-66706-8

Image Credits: AI Generated